The role of interferons in ovarian cancer progression: Hinderer or promoter?

Liu, Taiqing; Li, Yinqi; Wang, Xiaoyu; Yang, Xiaodong; Fu, Yunhai; Zheng, Yeteng; Gong, Hanlin; He, Zhiyao

doi:10.3389/fimmu.2022.1087620

Cited by 8 publications

(3 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, both subsets show the upregulation of pathways related to cell proliferation and interferon gamma. These findings were extensively demonstrated for BRCA1 mut cases; in fact, several authors proved that BRCA1 loss leads to transcriptional reprogramming in tumor cells involving type I IFN signaling ( 33 – 35 ).…”

Section: Discussionmentioning

confidence: 78%

Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers

Sahnane,

Libera,

Facchi

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionBRCA1 methylated (BRCA1met) epithelial ovarian cancer (EOC) is a recently defined and not well-investigated subset of neoplasms. To date, no studies have focused on the transcriptional profiles of BRCA1met cases, and, as a matter of fact, we still do not know if this subset of EOCs is similar, and to what extent, to BRCA1 mutated (BRCA1mut) cases.MethodsWe compared a group of 17 BRCA1met cases against 10 BRCA1mut cases using a subset of carefully selected 17 BRCAwt EOCs as a control group.ResultsFirst, BRCA1met cases showed a downregulation of the relative transcript, while this association was not observed for BRCA1mut EOCs. The BRCA1met group exhibited a general upregulation of homologous recombination (HR)-related genes, as well as BRCA1mut. Overall, BRCA1met had a different gene expression profile, characterized by diffuse downregulation, whereas BRCA1mut showed a general upregulation (p < 0.0001). Both BRCA1-defective groups showed a slightly activated immune response mediated by interferon (IFN) gamma pathways.DiscussionIn conclusion, even if the expression profile of many genes related to DNA damage and repair system is shared between BRCA1mut and BRCA1met EOCs supporting that BRCA1met EOCs may benefit from PARPi therapies, our data demonstrate that BRCA1mut and BRCA1met EOCs show different expression profiles, suggesting a different mechanism of carcinogenesis that can be reflected in different responses to therapies and disease recovery.

show abstract

Section: Discussionmentioning

confidence: 78%

Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers

Sahnane,

Libera,

Facchi

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The migration of immune cells to the EOC tumor is orchestrated by various cytokines and chemokines (reviewed in [ 35 , 36 , 37 ]). Chemokine CCL5, constitutively expressed by EOC cells, induces the infiltration of CD8 T cells [ 38 ].…”

Section: Introductionmentioning

confidence: 99%

“…Interferons play an important role in the TME by regulating the gene expression of tumor infiltrating lymphocytes (TILs) [ 37 ]. Plasmacytoid dendritic cells, CD8 T cells, NK cells and T cell helper 1 (Th1) CD4 T cells are major sources of IFNγ.…”

Section: Introductionmentioning

confidence: 99%

Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment

Pampeno,

Opp,

Hurtado

et al. 2024

IJMS

View full text Add to dashboard Cite

This review article provides a comprehensive overview of a novel Sindbis virus vaccine platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most lethal of all gynecological malignancies. The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed with advanced disease. Current treatment options are very aggressive and limited, resulting in tumor recurrences and 50–60% patient mortality within 5 years. The unique properties of armed oncolytic Sindbis virus vectors (SV) in vivo have garnered significant interest in recent years to potently target and treat ovarian cancer. We discuss the molecular biology of Sindbis virus, its mechanisms of action against ovarian cancer cells, preclinical in vivo studies, and future perspectives. The potential of Sindbis virus-based therapies for ovarian cancer treatment holds great promise and warrants further investigation. Investigations using other oncolytic viruses in preclinical studies and clinical trials are also presented.

show abstract